semaglutide vs tirzepatide cost study weight loss effectiveness ✨ 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤'𝐬 𝐌𝐮𝐬𝐭-𝐑𝐞𝐚𝐝 𝐢𝐧 𝐎𝐮𝐫 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 ✨ We're breaking down one of the biggest conversations in medical weight loss right now: Tirzepatide vs Oral Planning Your Payments: Semaglutide and

12-14 A1C reductions of 0.4% to 0.9% were observed in studies of exenatide, with higher reductions achieved at the 10 mcg twice-daily dose

Its the second daily oral medication to treat obesity and other weight-related conditions (Novo Nordisks oral Wegovy was the first) allowing patients to avoid having to give themselves injections

Moreover, both the number of cases and the prevalence of T2D and obesity have been steadily increasing worldwide over the past few decades

The first person to be successfully treated was Leonard Thompson (figure 7)

Philippaert et al., 2021)

Although we have long known that A1C targets are not effective, this guideline recommends focusing completely on cardiovascular and renal risk as long as A1C is less than 9%